274-79-3

Basic information

• Product Name: IMIDAZO[1,2-A]PYRAZINE
• Synonyms: IMIDAZO[1,2-A]PYRAZINE;HIMIDAZO(1,2-A)PYRAZINE;Zinc02569196;1,3a,6-Triazaindene;1,7-Diazaindolizine
• CAS NO: 274-79-3
• Molecular Formula: C₆H₅N₃
• Molecular Weight: 119.12
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Pyrazines
• Mol File: 274-79-3.mol
• Article Data: 18

Chemical Properties

• Melting Point: 90-94 °C
• Appearance: /
• Density: 1.29
• Refractive Index: 1.689
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.30±0.30(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-A]PYRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-A]PYRAZINE(274-79-3)
• EPA Substance Registry System: IMIDAZO[1,2-A]PYRAZINE(274-79-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 274-79-3(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyrazine is a chemical compound with a fused imidazole and pyrazine ring system. It is a heterocyclic compound that is commonly used in organic synthesis and pharmaceutical research. Imidazo[1,2-a]pyrazine has potential pharmacological activities, and its derivatives have been studied for their use as antiviral, antibacterial, and anticancer agents. The structure and properties of imidazo[1,2-a]pyrazine make it a valuable building block for the development of new drug candidates and other bioactive compounds. Its unique ring system and reactivity make it a versatile and important molecule in the field of medicinal chemistry.

InChI:InChI=1/C6H5N3/c1-3-9-4-2-8-6(9)5-7-1/h1-5H

Upstream product

• 5049-61-6 2-Aminopyrazine 
• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 7252-83-7 1-bromo-2,2-dimethoxyethane 
• 107-20-0 2-chloroethanal 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 

Downstream Products

• 155653-55-7 8-phenylimidazo<1,2-a>pyrazine 
• 936361-36-3 3,8-dibromo-imidazo[1,2-a]pyrazine 
• 1606131-60-5 5-(4-ethylphenyl)-3-(pyrimidin-5-yl)imidazo[1,2-a]pyrazine 
• 1606131-61-6 2-methoxy-5-(5-phenylimidazo[1,2-a]pyrazin-3-yl)benzonitrile 
• 1606131-62-7 3-(1-methyl-1H-pyrazol-4-yl)-5-phenylimidazo[1,2-a]pyrazine 
• 1606131-64-9 5-(5-(4-fluorophenyl)imidazo[1,2-a]pyrazin-3-yl)-2-methoxybenzonitrile 
• 1606131-66-1 3-(4-(ethylthio)phenyl)-5-(pyridin-3-yl)imidazo[1,2-a]pyrazine 
• 1606131-67-2 3-(4-(ethylthio)phenyl)-5-(2-methoxypyridin-4-yl)imidazo[1,2-a]pyrazine 
• 1606131-68-3 4-(3-(4-(ethylthio)phenyl)imidazo[1,2-a]pyrazin-5-yl)isoquinoline 
• 1606131-69-4 3-(3-(4-ethylphenyl)imidazo[1,2-a]pyrazin-5-yl)quinoline 
• 1606131-43-4 3-(4-(trifluoromethyl)phenyl)imidazo[1,2-a]pyrazine 
• 1606131-44-5 3-(4-(ethylthio)phenyl)imidazo[1,2-a]pyrazine 
• 1606131-45-6 2-imidazo[1,2-a]pyrazin-3-yl-5-methoxybenzonitrile 
• 1606131-46-7 3-(2,4-dimethylphenyl)imidazo[1,2-a]pyrazine 

Relevant articles and documents

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

A 5, 6, 7, 8-tetrahydro-imidazol [1,2-A] pyrazine synthetic method

The invention discloses a method for synthesizing 5,6,7,8-tetrahydroimidazole-[1,2-A]-pyrazine. The method comprises the following steps: reacting tetramethypyrazine with chloroacetaldehyde dimethyl to generate indol-[1,2-A]-pyrazine; performing hydrogenation reduction reaction on indol-[1,2-A]-pyrazine in the presence of a palladium-carbon catalyst to generate 5,6,7,8-tetrahydroimidazole-[1,2-A]-pyrazine. The method has the beneficial effects that the raw materials are easily available, the reaction conditions are mild, low-cost chloroacetaldehyde dimethyl and palladium-carbon catalyst are adopted, and the large-scale production is facilitated.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.